DOCSLIB.ORG

Modified Nucleosides Part A: a Platform for the Chemical Tagging of Ribonucleic Acids for Analysis by Mass Spectrometry Part B: Base-Modified Thymidines Exhibiting Cytotoxicity

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Modified Nucleosides Part A: a Platform for the Chemical Tagging of Ribonucleic Acids for Analysis by Mass Spectrometry Part B: Base-Modified Thymidines Exhibiting Cytotoxicity Modified Nucleosides Part A: A Platform for the Chemical Tagging of Ribonucleic Acids for Analysis by Mass Spectrometry Part B: Base-Modified Thymidines Exhibiting Cytotoxicity towards Cancer Cells A Dissertation Submitted to the Graduate School of the University of Cincinnati in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy (PhD) In the Department of Chemistry of McMicken College of Arts and Sciences By: Kayla Borland Aug 2018 University of Cincinnati Cincinnati, Ohio Abstract This dissertation is focused on modified nucleosides. Part A focuses on method development for multiplex analysis of modified oligonucleosides while part B is a medicinal chemistry perspective of modified nucleosides as potential anti-cancer therapeutics. Part A uses mass spectrometry (MS) as an enabling technology for the characterization of post- transcriptionally modified nucleosides within ribonucleic acids (RNAs). These modified RNAs tend to be more challenging to completely characterize using conventional genomic-based sequencing technologies. As with many biological molecules, information relating to the presence or absence of a particular compound (i.e., qualitative measurement) is only one step in sample characterization. Additional useful information is found by performing quantitative measurements on the levels of the compound of interest in the sample. To unlock this information within RNA samples, previously reported duplex-based strategies to characterize modified RNAs in two different samples have been examined. Here is reported the use of poly adenosine polymerase (PAP), which – under optimized conditions – can add one 2’ azido modified nucleotide to the 3’-terminus of modified RNA. The addition of this azido-modified nucleotide can allow for the use of click chemistry to uniquely tag each sample. One sample is labeled with an unisotopically labeled alkyne while the other samples are reacted with an isotopically labeled alkyne. The two samples can easily be compared to one another based on doublet separate by difference in isotopic label mass. In part B modified nucleoside are synthesized because, current FDA-approved anti-cancer modified nucleosides elicit severe side effects warranting their improvement. Therefore, a series of compounds with a mechanism of action focused on inhibiting DNA replication was designed. Compound were inspired by the previous discovery that 5-(α-substituted-2-nitrobenzyloxy)methyluridine-5’-triphosphates terminate DNA synthesis. Thus, a library of thymidine analogs were synthesized and evaluated using a cell viability assay in MCF7 breast cancer cells, which were chosen because they had the greatest susceptibility to these nucleosides. The structure-activity relationship study lead to a compounds having α-tert-butyl-2-nitro-4-(phenyl)alkynylbenzyloxy; it caused 50% of MCF7 cell death at 9 ± 1 µM concentration. iii Acknowledgments This dissertation is dedicated to my family and my friends that have become like family for their continued support, prayers, and encouragement. I would like to acknowledge Dr. Limbach and Dr Merino for all their guidance in my journey to become a better scientist. iv Table of Contents Abstract ………………………………………………………………………………………....ii Acknowledgments …………………………………………………………………….….……iv List of Figures …………………………………………………………………………..……...ix List of Tables …………………………………………………………………………………xiv Part A 1 Chapter 1 Introduction .........................................................................................................17 1.1 Research goal ...............................................................................................................17 1.2 Introduction to Mass Spectrometry of Modified Ribonucleic Acids ...........................17 1.3 Stable Isotope Labeling Methods for RNA Mass Spectrometry ..................................20 1.4 18O labeling .................................................................................................................23 1.4.1 18O Labeling of RNA – Early Applications for Mass Spectrometry ...................25 1.4.2 18O Labeling of RNA for Modification Mapping by Mass Spectrometry ...........30 1.5 Future Outlook .............................................................................................................36 2 Chapter 2 Multiplexing .......................................................................................................38 2.1 Background ..................................................................................................................38 v 2.2 Experimental ................................................................................................................39 2.2.1 Materials: ..............................................................................................................39 2.2.2 Identification of Optimal azido-modified dNTP...................................................39 2.2.3 Optimization of PAP reactions .............................................................................39 2.2.4 Click reaction optimization ...................................................................................40 2.2.5 Calibration curve ...................................................................................................40 2.2.6 Model duplexes .....................................................................................................41 2.2.7 LC-MS ..................................................................................................................41 2.3 Results and Discussion .................................................................................................42 2.3.1 Identification of optimal azido-modified dNTP ...................................................42 2.3.2 Optimization of PAP extension ............................................................................43 2.3.3 Click reaction optimization ...................................................................................45 2.3.4 Model Duplexing Studies .....................................................................................47 2.3.5 Relative Quantification of Oligonucleotide Modification Levels ........................49 2.4 Conclusion ....................................................................................................................50 3 Chapter 3 Conclusions and Future Work ............................................................................52 3.1 Conclusions ..................................................................................................................52 3.2 Future work ..................................................................................................................52 3.3 Additional alkynes tags ................................................................................................53 3.4 T1 removal or inactivation ...........................................................................................58 3.5 PAP extension of oligonucleotide ................................................................................64 vi 3.6 T4 ligation ....................................................................................................................66 4 Chapter 4 Introduction ........................................................................................................70 4.1 Research goal ...............................................................................................................70 4.2 Introduction ..................................................................................................................70 4.3 Current nucleobase-modified antimetabolite chemotherapeutic drugs ........................72 4.3.1 Modified nucleobase drugs ...................................................................................72 4.3.2 Base-modified natural sugar nucleoside drugs .....................................................73 4.3.3 Base-modified unnatural sugar nucleoside drugs .................................................75 4.3.4 Development of novel nucleobase-modified antimetabolite drug candidates ......78 4.4 Conclusions and outlook ..............................................................................................87 5 Chapter 5 Base-Modified Thymidines Capable of Terminating DNA Synthesis as Novel Drug Candidates Showing Activity in Cancer Cells...................................................................88 5.1 Background ..................................................................................................................88 5.2 Chemical synthesis .......................................................................................................89 5.2.1 Materials ...............................................................................................................89 5.2.2 Chemical Synthesis ...............................................................................................90 5.2.3 Synthesized Compounds .......................................................................................90 5.3 Biochemistry experiments ..........................................................................................110 5.3.1 Cell cytotoxicity assay (MTT) ............................................................................110 5.3.2 DNA synthesis termination studies .....................................................................110 5.4 Results/discussion ......................................................................................................113
Load more

Recommended publications
  • Deoxyribonucleic Acid Synthesis I. Effect of in Vivo Cyclophosphamide
    ICANCER RESEARCH 26 Part 1, 1466-1472,July 1966] Deoxyribonucleic Acid Synthesis I. Effect of in Vivo Cyclophosphamide Treatment on the in Vitro Activity of the Deoxyribonucleic Acid Synthetase System of Sensitive and Resistant Plasmacytomas1 ARTHUR J. TOMISEK, MARTHA BRUCE IRICK, AND PAULA WEDELES ALLAN Kettering'-Meyer Laboratory,2 Southern Research Institute, Birmingham, Alabama Summary term DNA-synthetase. In addition to this measurement of over-all DNA synthetase activity, we used the same experiments We have shown that the in vivo treatment of Fortner plasma- to determine the time course of radioactivity distribution among cytomas with Cyclophosphamide can lead to strong inhibitions of both deoxyribonucleic acid nucleotidyl transferase and thymi- the soluble components of the synthetase reaction mixtures. Our data show that the observed decreases in enzyme activity dylatc kinase activities in the soluble cell fractions. However, in are among the possible consequences of growth inhibition in the allowing only 2 hr for the inhibitor to act, the effect observed on tumor. the transferase was an unexplained stimulation rather than an inhibition. We have also provided some evidence that the inhibition of Materials and Methods growth precedes the inhibition of deoxyribonucleic acid nucleo ENZYME PREPARATION.Fortner hamster plasmacytoma tidyl transferase activity. ("sensitive") (3) and ite cyclophosphamide-resistant subline (12) were used for bilateral s.c. implantation into groups of 6-12 Introduction Golden Syrian hamsters, the animals in each experiment being uniform with respect to commercial subline, sex, and approxi Previous studies in this laboratory have shown that several mate age. On the 12th-14th postimplant day the animals were alkylating agents inhibited the in vivo synthesis of DNA by divided into 2 subgroups, to receive daily i.p.
    [Show full text]
  • On-Demand Synthesis of Phosphoramidites
    ARTICLE https://doi.org/10.1038/s41467-021-22945-z OPEN On-demand synthesis of phosphoramidites Alexander F. Sandahl1, Thuy J. D. Nguyen1, Rikke A. Hansen1, Martin B. Johansen 1, Troels Skrydstrup 1,2 & ✉ Kurt V. Gothelf 1,2 Automated chemical synthesis of oligonucleotides is of fundamental importance for the production of primers for the polymerase chain reaction (PCR), for oligonucleotide-based drugs, and for numerous other medical and biotechnological applications. The highly opti- mised automised chemical oligonucleotide synthesis relies upon phosphoramidites as the 1234567890():,; phosphate precursors and one of the drawbacks of this technology is the poor bench stability of phosphoramidites. Here, we report on the development of an on-demand flow synthesis of phosphoramidites from their corresponding alcohols, which is accomplished with short reaction times, near-quantitative yields and without the need of purification before being submitted directly to automated oligonucleotide synthesis. Sterically hindered as well as redox unstable phosphoramidites are synthesised using this methodology and the sub- sequent couplings are near-quantitative for all substrates. The vision for this technology is direct integration into DNA synthesisers thereby omitting manual synthesis and storage of phosphoramidites. 1 Interdisciplinary Nanoscience Center, iNANO, Aarhus University, Aarhus C, Denmark. 2 Department of Chemistry, Aarhus University, Aarhus C, Denmark. ✉ email: [email protected] NATURE COMMUNICATIONS | (2021) 12:2760 | https://doi.org/10.1038/s41467-021-22945-z | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-22945-z ynthetic oligonucleotides are essential for a range of dif- includetheuseofmechanochemistry11 or the use of P(V) chemistry Sferent areas and millions of oligonucleotides are synthesized to form the internucleosidic P–Obond12,13.
    [Show full text]
  • Structure and Function Of
    8/5/2019 DNA and RNA The Code of Life The Human Genome Project Gene Expression Genetic code The alphabet of the genetic code contains Genes are DNA sequences that encode proteins (the gene product) only four letters (A,T,G,C). Gene expression refers to the process A number of experiments confirmed that the whereby the information contained in genes genetic code is written in 3-letter words, each begins to have effects in the cell. of which codes for particular amino acid. DNA encodes and transmits the genetic A nucleic acid word (3 nucleotide letters) is information passed down from parents to offspring. referred to as a codon. 1 8/5/2019 Nucleic acids Nucleotides Principle information molecule in the Nucleotides are the unit structure of cell. nucleic acids. Nucleotides composed of 3 All the genetic codes are carried out on components: the nucleic acids. Nitrogenous base (A, C, G, T or U) Pentose sugar Nucleic acid is a linear polymer of Phosphate nucleotides Nucleotides Nitrogenous bases There are four nitrogen bases making up four different nucleotides. There are 2 types: Purines(pyoo r-een): Adenine A Two ring structure Purines Adenine (A) and Guanine (G) Guanine G Pyrimidines(pahy-rim-i-deen,): N base Single ring structure Cytosine (C) and Thymine (T) or Uracil (U). Thymine T Pyrimidines Cytosine C 2 8/5/2019 A NUCLEOTIDE Nucleotide bases 1. Phosphate Group 2.3. 5Nitrogen-Carbon BaseSugar 1. Phosphate Group 2. 5-Carbon Sugar (Dexoyribose or Ribose) 3. (Dexoyribose or Ribose) 1. 3. Nitrogen Base 2. 3. Nucleotides, too O 1.
    [Show full text]
  • Nucleotide Metabolism 22
    Nucleotide Metabolism 22 For additional ancillary materials related to this chapter, please visit thePoint. I. OVERVIEW Ribonucleoside and deoxyribonucleoside phosphates (nucleotides) are essential for all cells. Without them, neither ribonucleic acid (RNA) nor deoxyribonucleic acid (DNA) can be produced, and, therefore, proteins cannot be synthesized or cells proliferate. Nucleotides also serve as carriers of activated intermediates in the synthesis of some carbohydrates, lipids, and conjugated proteins (for example, uridine diphosphate [UDP]-glucose and cytidine diphosphate [CDP]- choline) and are structural components of several essential coenzymes, such as coenzyme A, flavin adenine dinucleotide (FAD[H2]), nicotinamide adenine dinucleotide (NAD[H]), and nicotinamide adenine dinucleotide phosphate (NADP[H]). Nucleotides, such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), serve as second messengers in signal transduction pathways. In addition, nucleotides play an important role as energy sources in the cell. Finally, nucleotides are important regulatory compounds for many of the pathways of intermediary metabolism, inhibiting or activating key enzymes. The purine and pyrimidine bases found in nucleotides can be synthesized de novo or can be obtained through salvage pathways that allow the reuse of the preformed bases resulting from normal cell turnover. [Note: Little of the purines and pyrimidines supplied by diet is utilized and is degraded instead.] II. STRUCTURE Nucleotides are composed of a nitrogenous base; a pentose monosaccharide; and one, two, or three phosphate groups. The nitrogen-containing bases belong to two families of compounds: the purines and the pyrimidines. A. Purine and pyrimidine bases Both DNA and RNA contain the same purine bases: adenine (A) and guanine (G).
    [Show full text]
  • European Patent Office *% a a N4 © Publication Number: 0 344 937 B1 Office Europeen Des Brevets
    Europa,schesP_ MM M II M MM M MINI Ml M I II J European Patent Office *% A a n4 © Publication number: 0 344 937 B1 Office europeen des brevets © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 13.07.94 © Int. CI.5: C12P 19/38, C12P 17/12, C12N 1/20 © Application number: 89304820.7 @ Date of filing: 12.05.89 © Production of a deoxyrlbonucleoslde. ® Priority: 31.05.88 GB 8812846 (73) Proprietor: ZENECA LIMITED 22.03.89 GB 8906623 Imperial Chemical House, 9 Millbank London SW1P 3JF(GB) @ Date of publication of application: 06.12.89 Bulletin 89/49 @ Inventor: Naylor, Linda Anne Daphne House © Publication of the grant of the patent: 6 West Green 13.07.94 Bulletin 94/28 Helghlngton Village Newton Aye I if fe Co.Durham(GB) © Designated Contracting States: AT BE CH DE ES FR GB GR IT LI LU NL SE © Representative: Locke, Timothy John et al © References cited: ICI Group Patents Services Dept. FR-A- 2 126 437 PO Box 6 Shire Park Bessemer Road Welwyn Garden City Herts, AL7 1HD (GB) 00 IV CO Oi oo Note: Within nine months from the publication of the mention of the grant of the European patent, any person ® may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition CL shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee LU has been paid (Art. 99(1) European patent convention). Rank Xerox (UK) Business Services (3.
    [Show full text]
  • 1/05661 1 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date _ . ... - 12 May 2011 (12.05.2011) W 2 11/05661 1 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/00 (2006.0 1) C12Q 1/48 (2006.0 1) kind of national protection available): AE, AG, AL, AM, C12Q 1/42 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) Number: International Application DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 10/054171 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 26 October 2010 (26.10.2010) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/255,068 26 October 2009 (26.10.2009) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, MYREXIS, INC.
    [Show full text]
  • Chemoenzymatic Synthesis of Nucleoside Analogs As Potential Medicinal Agents
    Chemoenzymatic synthesis of nucleoside analogs as potential medicinal agents vorgelegt von M. Sc. Heba Yehia Mohamed ORCID: 0000-0002-3238-0939 von der Fakultät III-Prozesswissenschaften der Technischen Universität Berlin zur Erlangung des akademischen Grades Doktorin der Naturwissenschaften - Dr. rer. nat. – genehmigte Dissertation Promotionsausschuss: Vorsitzender: Prof. Dr. Roland Lauster, Medical Biotechnology, TU Berlin, Berlin Gutachter: Prof. Dr. Peter Neubauer, Bioprocess Engineering, TU Berlin, Berlin Gutachter: Prof. Dr. Jens Kurreck, Applied Biochemistry, TU Berlin, Berlin Gutachter: Prof. Dr. Vlada B. Urlacher, Biochemistry, Heinrich-Heine-Universität Düsseldorf, Düsseldorf Tag der wissenschaftlichen Aussprache: 16. Juli 2019 Berlin, 2019 Heba Y. Mohamed Synthesis of nucleoside analogs as potential medicinal agents Abstract Modified nucleosides are important drugs used to treat cancer, viral or bacterial infections. They also serve as precursors for the synthesis of modified oligonucleotides (antisense oligonucleotides (ASOs) or short interfering RNAs (siRNAs)), a novel and effective class of therapeutics. While the chemical synthesis of nucleoside analogs is challenging due to multi-step procedures and low selectivity, enzymatic synthesis offers an environmentally friendly alternative. However, current challenges for the enzymatic synthesis of nucleoside analogs are the availability of suitable enzymes or the high costs of enzymes production. To address these challenges, this work focuses on the application of thermostable purine and pyrimidine nucleoside phosphorylases for the chemo-enzymatic synthesis of nucleoside analogs. These enzymes catalyze the reversible phosphorolysis of nucleosides into the corresponding nucleobase and pentofuranose-1-phosphate and have already been successfully used for the synthesis of modified nucleosides in small scale. So far, the production of sugar-modified nucleosides has been a major challenge.
    [Show full text]
  • Download PDF of Article
    research papers 7-Iodo-5-aza-7-deazaguanine ribonucleoside: crystal structure, physical properties, base-pair stability and functionalization ISSN 2053-2296 Dasharath Kondhare,a Simone Budow-Busse,a Constantin Daniliucb and Frank Seelaa,c* Received 19 February 2020 aLaboratory of Bioorganic Chemistry and Chemical Biology, Center for Nanotechnology, Heisenbergstrasse 11, 48149 Accepted 3 April 2020 Mu¨nster, Germany, bOrganisch-Chemisches Institut, Westfa¨lische Wilhelms-Universita¨tMu¨nster, Corrensstrasse 40, 48149 Mu¨nster, Germany, and cLaboratorium fu¨r Organische und Bioorganische Chemie, Institut fu¨r Chemie, Universita¨t Edited by D. S. Yufit, University of Durham, Osnabru¨ck, Barbarastrasse 7, 49069 Osnabru¨ck, Germany. *Correspondence e-mail: [email protected] England Keywords: 7-iodo-5-aza-7-deazaguanosine; The positional change of nitrogen-7 of the RNA constituent guanosine to the ribonucleoside; crystal structure; Hirshfeld bridgehead position-5 leads to the base-modified nucleoside 5-aza-7-deaza- surface analysis; base-pair prediction; crystal guanosine. Contrary to guanosine, this molecule cannot form Hoogsteen base packing; all-purine RNA; pKa values. pairs and the Watson–Crick proton donor site N3—H becomes a proton- acceptor site. This causes changes in nucleobase recognition in nucleic acids and CCDC reference: 1950946 has been used to construct stable ‘all-purine’ DNA and DNA with silver- Supporting information: this article has mediated base pairs. The present work reports the single-crystal X-ray structure supporting information at journals.iucr.org/c of 7-iodo-5-aza-7-deazaguanosine, C10H12IN5O5 (1). The iodinated nucleoside shows an anti conformation at the glycosylic bond and an N conformation (O40- endo) for the ribose moiety, with an antiperiplanar orientation of the 50-hydroxy group.
    [Show full text]
  • Interrelations Between Substrate Cycles and De Novo
    Proc. Nati. Acad. Sci. USA Vol. 83, pp. 986-990, February 1986 Cell Biology Interrelations between substrate cycles and de novo synthesis of pyrimidine deoxyribonucleoside triphosphates in 3T6 cells (hydroxyurea/nucleoside incorporation/metabolic flux) VERA BIANCHI, ELISABET PONTIS, AND PETER REICHARD* Medical Nobel Institute, Department of Biochemistry I, Karolinska Institutet, Box 60400, S104 01 Stockholm, Sweden Contributed by Peter Reichard, September 23, 1985 ABSTRACT Degradation of pyrimidine deoxyribonucleo- but also resulted in a continued uptake and net phosphoryl- side triphosphates plays a major role in the regulation of their ation of deoxyuridine. This effect was secondary to a large pool sizes in 3T6 cells. During normal growth, these cells drop in the intracellular dUMP pool. We propose that excrete deoxyribonucleosides (mostly deoxyuridine) into the deoxyuridine and dUMP form a substrate cycle and that the medium. When DNA strand elongation is inhibited, de novo operative direction of this cycle is regulated by the intracel- synthesis of dCTP and dTTP continues, followed by degrada- lular concentration of dUMP. tion of the deoxyribonucleotides. We now demonstrate that inhibition of de novo synthesis with hydroxyurea stops degra- AND dation of deoxyribonucleotides and leads to an influx of MATERIALS METHODS deoxyuridine from the medium. This effect appears to be Materials. Deoxy[6-3H]uridine (21 Ci/mmol; l Ci = 37 caused by a large drop in the size of the intracellular dUMP GBq) was from New England Nuclear Dupont, and [5- pool. We propose that substrate cycles, involving phosphoryl- 3H]cytidine (25-30 Ci/mmol) and [3H]dNTPs and [a-32P]- ation of deoxyribonucleosides by kinases and dephosphoryla- dNTPs were from Amersham.
    [Show full text]
  • Ribonucleosides for an Artificially Expanded Genetic Information
    Note pubs.acs.org/joc Ribonucleosides for an Artificially Expanded Genetic Information System † ‡ † ‡ † § † § Hyo-Joong Kim, , Nicole A. Leal, , Shuichi Hoshika, , and Steven A. Benner*, , † Foundation for Applied Molecular Evolution (FfAME), 720 SW Second Avenue, Suite 201, Gainesville, Florida 32601, United States ‡ Firebird Biomolecular Sciences LLC, 13709 Progress Boulevard, Box 17, Alachua, Florida 32615, United States § The Westheimer Institute for Science and Technology (TWIST), 720 SW Second Avenue, Suite 208, Gainesville, Florida 32601, United States *S Supporting Information ABSTRACT: Rearranging hydrogen bonding groups adds nucleobases to an artificially expanded genetic information system (AEGIS), pairing orthogonally to standard nucleotides. We report here a large-scale synthesis of the AEGIS nucleotide carrying 2- amino-3-nitropyridin-6-one (trivially Z) via Heck coupling and a hydroboration/oxidation sequence. RiboZ is more stable against epimerization than its 2′-deoxyribo analogue. Further, T7 RNA polymerase incorporates ZTP opposite its Watson−Crick comple- ment, imidazo[1,2-a]-1,3,5-triazin-4(8H)one (trivially P), laying grounds for using this “second-generation” AEGIS Z:P pair to add amino acids encoded by mRNA. ne of many accomplishments of synthetic biology over Because of their orthogonality, “first-generation” AEGIS pairs O the past two decades has been the generation of DNA are today used widely. In the clinic, AEGIS DNA is used to “ ” monitor the load of viruses in the blood of patients infected systems that have
    [Show full text]
  • Adenosine Triphosphate - Wikipedia, the Free Encyclopedia
    Adenosine triphosphate - Wikipedia, the free encyclopedia http://en.wikipedia.org/wiki/Adenosine_triphosphate Adenosine triphosphate From Wikipedia, the free encyclopedia Adenosine- Adenosine triphosphate 5'-triphosphate (ATP) is a multifunctional nucleotide used in cells as a coenzyme. It is often called the "molecular unit of currency" of intracellular energy transfer.[1] ATP transports chemical energy within cells for metabolism. It is produced by photophosphorylation and cellular respiration and used by enzymes and structural proteins in many cellular processes, including biosynthetic reactions, motility, and cell division.[2] One molecule of ATP contains three phosphate groups, and it is produced by ATP synthase from IUPAC name inorganic phosphate [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl(hydroxy- and adenosine phosphonooxyphosphoryl)hydrogen phosphate diphosphate (ADP) or Other names adenosine adenosine 5'-(tetrahydrogen triphosphate) monophosphate Identifiers CAS 56-65-5 (AMP). number PubChem 5957 Metabolic processes ChemSpider 5742 that use ATP as an IUPHAR 1713 energy source convert ligand it back into its SMILES precursors. ATP is O=P(O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n2cnc1c(ncnc12)N) [C@H](O)[C@@H]3O therefore 1 of 14 6/3/10 6:02 PM Adenosine triphosphate - Wikipedia, the free encyclopedia http://en.wikipedia.org/wiki/Adenosine_triphosphate continuously recycled InChI in organisms: the 1/C10H16N5O13P3 human body, which /c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(26-10)1-25-30(21,22)28-31(23,24)27-29(18,19)20
    [Show full text]
  • Natural Versus Artificial Creation of Base Pairs in DNA: Origin Of
    Natural versus Artificial Creation of Base Pairs in DNA: Origin of Nucleobases from the Perspectives of Unnatural Base Pair Studies † ‡ † ‡ ICHIRO HIRAO,*, , MICHIKO KIMOTO, , AND † RIE YAMASHIGE † RIKEN Systems and Structural Biology Center (SSBC), 1-7-22 Suehiro-cho, ‡ Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan, and TagCyx Biotechnologies, 1-6-126 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan RECEIVED ON OCTOBER 6, 2011 CONSPECTUS ince life began on Earth, the four types of bases (A, G, C, and S T(U)) that form two sets of base pairs have remained unchanged as the components of nucleic acids that replicate and transfer genetic information. Throughout evolution, except for the U to T modification, the four base structures have not changed. This constancy within the genetic code raises the question of how these complicated nucleotides were generated from the molecules in a primordial soup on the early Earth. At some prebiotic stage, the complementarity of base pairs might have accelerated the generation and accumulation of nucleotides or oligonucleotides. We have no clues whether one pair of nucleobases initially appeared on the early Earth during this process or a set of two base pairs appeared simultaneously. Recently, researchers have developed new artificial pairs of nucleobases (unnatural base pairs) that function alongside the natural base pairs. Some unnatural base pairs in duplex DNA can be efficiently and faithfully amplified in a polymerase chain reaction (PCR) using thermostable DNA polymerases. The addition of unnatural base pair systems could expand the genetic alphabet of DNA, thus providing a new mechanism for the generation novel biopolymers by the site-specific incorporation of functional components into nucleic acids and proteins.
    [Show full text]